West Virginia asks judge to dismiss lawsuit seeking to overturn state restrictions on abortion pill

West Virginia asks judge to dismiss lawsuit seeking to overturn state restrictions on abortion pill


West Virginia’s attorney general is urging a judge to dismiss a lawsuit seeking to overturn the state’s restrictions on the abortion pill.

State Attorney General Patrick Morrisey on Tuesday asked the federal court in West Virginia’s southern district to throw out the suit brought by GenBioPro, which manufactures the generic version of the abortion pill called mifepristone.

GenBioPro sued West Virginia in January, arguing that the Food and Drug Administration’s powers to approve and regulate medications pre-empt the state’s restrictions on the abortion pill.

“A State’s police power does not extend to functionally banning an article of interstate commerce — the Constitution leaves that to Congress,” GenBioPro’s lawyers wrote.

The case is one in a series of ongoing legal battles in federal courts around the U.S. over the FDA’s two-decade-old approval of mifepristone. In Texas, anti-abortion physicians have asked a federal judge to overturn the agency’s approval and pull the pill from the U.S. market.

West Virginia’s attorney general said the FDA does not have the power to set abortion policy nationwide through its approval of mifepristone. He described GenBioPro’s argument as a “breathtaking assertion of federal agency power.” The Supreme Court gave states the power to regulate abortion after overturning Roe v. Wade last June, he argued.

“Congress did not silently cede this vast area of historically state regulation to the FDA,” Morrisey argued in the court filing.

GenBioPro has asked the court to declare unconstitutional West Virginia’s law that bans abortion with a few exceptions. The state allows abortions when a medical professional determines the mother’s life is in danger or the child is not viable. Abortion is also allowed in cases of rape or incest before the eighth week of pregnancy for an adult or the 14th week for a minor.

Morrisey said mifepristone is legal for use in West Virginia in those circumstances. The FDA has approved the pill for use through the 10th week of pregnancy.

West Virginia does not allow patients to obtain a prescription for mifepristone through telemedicine appointments. The FDA, on the other hand, has gradually done away with federal regulations that required in-person visits, now allowing patients to obtain prescriptions for the pill through telemedicine and have it delivered by mail.

“West Virginia retains the police power to regulate how drugs may be prescribed and dispensed by medical professionals,” Morrisey argued.

Join CNBC’s Healthy Returns on March 29th, where we’ll convene a virtual gathering of CEOs, scientists, investors and innovators in the health care space to reflect on the progress made today to reinvent the future of medicine. Plus, we’ll have an exclusive rundown of the best investment opportunities in biopharma, health-tech and managed care. Learn more and register today: 



Source

CDC takes down more than a dozen webpages on sexual and gender identity, health equity
Health

CDC takes down more than a dozen webpages on sexual and gender identity, health equity

A sign for the CDC sits outside of their facility at the Centers for Disease Control and Prevention Roybal campus in Atlanta, Georgia, U.S., May 30, 2025. Megan Varner | Reuters More than a dozen pages on the Centers for Disease Control and Prevention website related to sexual and gender identity, health equity, and other […]

Read More
We’re buying the dip in a health and life sciences stock that has gone down enough
Health

We’re buying the dip in a health and life sciences stock that has gone down enough

We’re buying 20 more shares of Danaher at roughly $180 each. Following Thursday’s trade, Jim Cramer’s Charitable Trust will own 470 shares of DHR, increasing its weighting to about 2.31% from about 2.22%. While Danaher has certainly been one of a handful of problematic stocks in the portfolio, we are stepping into the name here, […]

Read More
Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial
Health

Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial

The Roche Holding AG headquarters on April 11, 2025, in Basel, Switzerland. Sedat Suna | Getty Images News | Getty Images Swiss pharmaceutical firm Roche is targeting becoming a top three obesity player globally, posing a potential rival to heavyweights Novo Nordisk and Eli Lilly as it advances one of its experimental weight-loss drugs to […]

Read More